Tag: global neurodegenerative disease market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Neurodegenerative Disorder Therapeutics Market Revenue Growth On Track For A 9.6% CAGR Through 2030

The neurodegenerative disorder therapeutics market has shown substantial growth over the past few years. This market is expected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. The rise observed in previous periods is attributable to the increasing incidence of neurodegenerative diseases, an expanding elderly population, restricted availability of treatment options, enhanced awareness for prompt diagnosis, and improvements in hospital and neurology care facilities.

The neurodegenerative disorder therapeutics market is projected to experience substantial expansion over the coming years, reaching $34.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is fueled by several factors, including the progress in gene therapies, improvements in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring systems, increased funding for clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Key trends expected during this period involve the wider acceptance of neuroprotective and neurorestorative treatments, an increased emphasis on managing symptoms and providing patient-centered care, a rise in clinical trials for new neurodegenerative medications, the proliferation of personalized and targeted therapeutic methods, and the merging of home care with remote monitoring solutions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=35759531&type=smp&name=Neurodegenerative%20Disorder%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurodegenerative Disorder Therapeutics Market Growth Catalysts And Demand Drivers

Increased investment in research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to drive the expansion of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations are undertaking these R&D investments for neurodegenerative disorders due to various persuasive reasons, such as rising prevalence, significant unaddressed medical requirements, economic ramifications, and global health initiatives. For instance, in March 2023, the Government of Canada, a federal administration based in Canada, announced a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, a continued increase in research and development (R&D) investment for neurodegenerative disorder therapeutics will fuel the growth of the neurodegenerative disorder therapeutics market during the forecast period.

Neurodegenerative Disorder Therapeutics Market Segmentation: How Does The Market Break Down By Category?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Neurodegenerative Disorder Therapeutics Market Trends Shaping Long-Term Demand

Leading companies within the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that the body metabolically converts into active drugs, enabling a controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Neurodegenerative Disorder Therapeutics Market Competitive Overview And Top Companies

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

View The Full Neurodegenerative Disorder Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurodegenerative Disorder Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Neurodegenerative Disorder Therapeutics Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for therapeutics targeting neurodegenerative disorders has experienced robust expansion over the past several years. It is projected to rise from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth was driven by factors such as the increasing incidence of neurodegenerative conditions, a growing elderly demographic, insufficient therapeutic alternatives, heightened awareness surrounding early detection, and the ongoing development of hospital and neurology care facilities.

The neurodegenerative disorder therapeutics market is projected to experience robust expansion over the coming years, with an anticipated rise to $34.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.6%. This forecast period growth is driven by several key developments, including the emergence of gene therapies, progress in monoclonal antibody-based treatments, the incorporation of artificial intelligence-powered diagnostic and monitoring tools, increased funding for clinical research and trials, and the broadening of personalized medicine and targeted therapeutics. Among the prominent trends shaping this period are a growing utilization of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an expansion of clinical trial activities focused on novel neurodegenerative drugs, a further advancement of personalized and targeted therapeutic strategies, and the integration of home care solutions with remote monitoring technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neurodegenerative Disorder Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?

The anticipated rise in funding directed toward research and development (R&D) for treatments of neurodegenerative disorders is set to fuel expansion within the neurodegenerative disorder therapeutics market moving forward. Such investments are initiated by governments and organizations for several strong reasons, including the growing frequency of these conditions, substantial gaps in existing medical care, associated economic burdens, and worldwide health priorities. As an example, in March 2023, the Government of Canada, a federal entity based in Canada, disclosed a $38.3 million commitment to support research on neurodegenerative diseases. Consequently, this sustained increase in R&D investment for neurodegenerative disorder therapies will keep driving market growth throughout the forecast period.

Neurodegenerative Disorder Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Neurodegenerative Disorder Therapeutics Market Trends: What Is Shaping Future Industry Growth?

Key players in the neurodegenerative disorder therapeutics market are placing increased emphasis on creating novel treatment strategies, including prodrug formulations, designed to boost the bioavailability, effectiveness, and safety profile of therapies for Parkinson’s disease. Prodrugs, which are biologically inactive substances that undergo metabolic conversion into their active pharmacological forms within the body, enable a regulated and prolonged release of active pharmaceutical ingredients. A notable example occurred in January 2024, when AbbVie Inc., a biopharmaceutical firm based in the United States, introduced PRODUODOPA (foslevodopa or foscarbidopa) across the European Union for individuals suffering from advanced Parkinson’s disease. This approach uses a soluble prodrug combination to ensure continuous levodopa administration, with the goal of minimizing motor fluctuations and enhancing patients’ overall quality of life. By providing an alternative to conventional intermittent oral dosing and supporting better adherence to treatment, this product launch marks a crucial step forward in the management of advanced Parkinson’s disease.

Neurodegenerative Disorder Therapeutics Market Key Players And Strategic Industry Positioning

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neurodegenerative Disorder Therapeutics Market Largest Region By Revenue And Market Share

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Neurodegenerative Disorder Therapeutics Market Compare Between 2026 And 2030?

The neurodegenerative disorder therapeutics market size has seen strong growth in recent years. It is anticipated to increase from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. The expansion observed in previous periods can be linked to the rising prevalence of neurodegenerative conditions, an expanding aging population, limited therapeutic options, increased awareness surrounding early diagnosis, and the development of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is expected to show significant growth in the upcoming period. It is forecast to grow to $34.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This expansion over the forecast period is driven by factors such as the development of gene therapies, advances in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, a rise in investment for clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Notable trends during this time include the increasing adoption of neuroprotective and neurorestorative therapies, a growing emphasis on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

Which Major Factors Are Contributing To The Development Of The Neurodegenerative Disorder Therapeutics Market?

Growing spending on research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to boost the expansion of the neurodegenerative disorder therapeutics market. Governments and various organizations initiate R&D investments in neurodegenerative disorders due to several crucial factors, such as the rising incidence, considerable unmet patient needs, economic consequences, and global health objectives. For example, in March 2023, the Government of Canada, a federal administration, disclosed an investment of $38.3 million to advance research in neurodegenerative diseases. Consequently, continued investment in R&D for neurodegenerative disorder therapeutics is expected to fuel the market’s expansion in the foreseeable future.

How Is The Neurodegenerative Disorder Therapeutics Market Distributed Across Key Segments?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Influencing The Expansion Of The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are directing their efforts towards developing innovative treatment options, such as prodrug formulations, to improve the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs within the body, facilitating controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and enhance patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Area Represents The Largest Portion Of The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurodegenerative Disorder Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Neurodegenerative Disorder Therapeutics Market Expected To Change From 2026 To 2030?

The market for neurodegenerative disorder therapeutics has witnessed substantial expansion in recent years. Its value is set to increase from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The previous period’s growth can be attributed to several factors including the rising incidence of neurodegenerative conditions, an expanding aging population, the limited array of available treatments, increasing public understanding of the benefits of early diagnosis, and the improvement of hospital and neurological care infrastructure.

The neurodegenerative disorder therapeutics market is expected to experience significant growth over the next few years, with its size projected to reach $34.13 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This expansion during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Significant trends for this period encompass the growing adoption of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an increase in clinical trials for innovative neurodegenerative drugs, the wider use of personalized and targeted therapeutic methods, and the integration of home care and remote monitoring solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Key Drivers Are Fueling The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Rising financial allocation towards research and development (R&D) in the field of neurodegenerative disorder therapeutics is projected to fuel the expansion of the neurodegenerative disorder therapeutics market moving ahead. Funding for research and development concerning neurodegenerative disorders is initiated by governmental bodies and organizations due to several strong factors, such as the growing incidence, substantial unaddressed medical requirements, financial implications, worldwide health endeavors, among others. As an illustration, in March 2023, the Government of Canada, a Canada-based federal administration, announced in 2023 a financial commitment of $38.3 million dedicated to furthering research into neurodegenerative diseases. Consequently, an escalating commitment to research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to consistently propel the expansion of the neurodegenerative disorder therapeutics market throughout the projected timeframe.

How Is The Neurodegenerative Disorder Therapeutics Market Organized By Segment Classification?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

What Trends Are Affecting The Direction Of The Neurodegenerative Disorder Therapeutics Market?

Leading companies in the neurodegenerative disorder therapeutics market are concentrating on creating innovative treatment options, such as prodrug formulations, to enhance the bioavailability, effectiveness, and safety profiles of Parkinson’s disease therapies. Prodrugs are inert compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy leverages a soluble prodrug combination to ensure continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. The launch signifies a considerable advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and enhancing treatment adherence.

Who Are The Industry Participants Involved In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Get The Full Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is The Largest In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurodegenerative Disorder Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Neurodegenerative Disorder Therapeutics Market From 2026 To 2030?

The neurodegenerative disorder therapeutics market size has shown robust growth in recent years. It is anticipated to expand from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth can be ascribed to several factors, including the increasing incidence of neurodegenerative disorders, a growing elderly population, restricted availability of treatment options, greater awareness leading to early diagnosis, and enhancements in hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is anticipated to experience robust expansion in the coming years. It is forecast to achieve a value of $34.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This projected growth throughout the forecast period stems from factors such as the development of gene therapies, advancements in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Prominent trends for the forecast period include the rising adoption of neuroprotective and neurorestorative therapies, a greater focus on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Key Drivers Are Influencing The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Heightened investment in research and development (R&D) for neurodegenerative disorder therapeutics is expected to propel the growth of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations initiate investments in research and development for neurodegenerative disorders for various compelling reasons, including their increasing prevalence, significant unmet medical needs, economic repercussions, global health initiatives, and more. For instance, in March 2023, according to Government of Canada, a Canada-based federal administration, the government of Canada revealed a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics will continue to drive the growth of the neurodegenerative disorder therapeutics market in the forecast period.

Which Segments Are Included In The Analysis Of The Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Impacting The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are focusing on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs in the body, allowing for controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. The therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Which Key Industry Participants Are Active In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Read the full neurodegenerative disorder therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurodegenerative Disorder Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurodegenerative disorder therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market size has experienced robust expansion over the past few years. This market is projected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Historically, this growth has been driven by factors such as the increasing prevalence of neurodegenerative disorders, a burgeoning aging population, the presence of limited treatment options, heightened awareness regarding early diagnosis, and the development of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market is poised for substantial expansion in the coming years. This market is projected to reach $34.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Significant trends over the forecast period are expected to include the increasing adoption of neuroprotective and neurorestorative therapies, a heightened focus on symptom management and patient-centric care, a rise in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the incorporation of home care and remote monitoring solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Drivers Are Supporting Technological Adoption In The Neurodegenerative Disorder Therapeutics Market?

Enhanced financial commitment to research and development (R&D) for neurodegenerative disorder treatments is projected to fuel the expansion of the neurodegenerative disorder therapeutics market in the future. Governments and various organizations initiate these R&D investments in neurodegenerative disorders due to several pressing factors, such as the rising incidence, considerable unmet healthcare demands, economic impacts, and worldwide health endeavors, among others. For instance, in March 2023, the Government of Canada, a Canada-based federal administration, disclosed a $38.3 million investment in 2023, dedicated to boosting research into neurodegenerative diseases. Consequently, sustained investment in R&D for neurodegenerative disorder therapeutics is anticipated to continuously spur the growth of the neurodegenerative disorder therapeutics market throughout the forecast timeframe.

Which Segments Are Contributing To The Growth Of The Neurodegenerative Disorder Therapeutics Market?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Expected To Influence The Neurodegenerative Disorder Therapeutics Market In The Upcoming Years?

Major companies in the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, particularly prodrug formulations, to enhance the bioavailability, efficacy, and safety profiles of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurodegenerative Disorder Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Neurodegenerative Disorder Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?

The market for therapeutics for neurodegenerative disorders has seen a robust growth recently. It is predicted to expand from $18.53 billion in 2024 to $20.04 billion in 2025, progressing at a compound annual growth rate (CAGR) of 8.1%. The past growth in the market can be traced back to factors like an increasing aging population, a higher occurrence of neurodegenerative disorders, increased life expectancy, greater investments from pharmaceutical firms, and heightened awareness and advocacy initiatives.

What Is the Forecast for the Neurodegenerative Disorder Therapeutics Market Size Through 2029?

The market for therapeutic solutions for neurodegenerative disorders is forecasted to experience substantial growth in the coming years. The market is projected to reach a value of $28.33 billion by 2029, achieving a Compound Annual Growth Rate (CAGR) of 9.0%. This growth is set to be fueled by a number of factors such as the increasing demand for personalized and targeted therapies, the widespread availability of clinical trials, and an overall increase in healthcare expenditure. Notable developments predicted for this period include therapies that modify the course of the disease, non-drug-based interventions, the use of telemedicine and remote monitoring, technological advancements, precision therapies, digital health initiatives, and trials centered around specific biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What are the Key Market Players in Neurodegenerative Disorder Therapeutics Market and How They’re Evolving?

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

What Are the Primary Growth Drivers in the Neurodegenerative Disorder Therapeutics Market?

The growth of the neurodegenerative disorder therapeutics market is being fuelled by a rising incidence of neurodegenerative disorders among the global populace. This increase is driven in part by the rise in the elderly population, which has a higher occurrence of these conditions. As per the World Population Prospects data, by 2024, we are looking at a jump in individuals over 60 years old to 2.1 billion by 2050, while those over the age of 80 will have grown threefold to 425 million. Furthermore, figures from the Alzheimer’s Association reveal that nearly 5.8 million US citizens are battling Alzheimer’s disease, with the forecast indicating a surge to approximately 14 million by 2050. Hence, with an escalating occurrence of neurodegenerative diseases in the older demographic, the need for neurodegenerative disorder therapeutics amplifies, prompting the progression of the market in this field.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp

What Are the Leading Segments in the Global Neurodegenerative Disorder Therapeutics Industry?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

What Are the Key Market Trends in the Neurodegenerative Disorder Therapeutics Industry?

Firms dealing with therapeutic treatments for neurodegenerative disorders are forming various strategic alliances with both governmental and non-governmental entities in order to explore and establish new therapies for an array of neurodegenerative diseases. There is also a rise in cooperation among participants in the neurodegenerative disorders therapeutics sector to amplify their research and development capabilities, with a focus on creating innovative and more successful treatment options. In a specific example from July 2022, NRG Therapeutics, a UK-based company that specialises in therapeutic solutions, collaborated with Domainex, a UK-based drug discovery service. The aim of their partnership is to collectively develop unique small-molecule disease-altering medications that can effectively treat Parkinson’s disease, motor neuron disease (MND) and other severe chronic neurodegenerative conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

What Is the Regional Outlook for the Neurodegenerative Disorder Therapeutics Market?

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818

This Report Delivers Insight On:

1. How big is the neurodegenerative disorder therapeutics market, and how is it changing globally?

2. Who are the major companies in the neurodegenerative disorder therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the neurodegenerative disorder therapeutics market right now?

4. Which products or customer segments are growing the most in the neurodegenerative disorder therapeutics market?

5. What factors are helping or slowing down the growth of the neurodegenerative disorder therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the neurodegenerative disorder therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Neurodegenerative Disorder Therapeutics Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

In recent years, the market size for therapeutics for neurodegenerative disorders has experienced significant growth. It is set to expand from $18.53 billion in 2024 to $20.04 billion in 2025, marking a compound annual growth rate (CAGR) of 8.1%. Factors that have contributed to the growth in the historic period include an aging population, an increase in cases of neurodegenerative disorders, longer life expectancy, heightened investments by pharmaceutical companies, and a rise in awareness and advocacy._x000D_

_x000D_

In the upcoming years, the neurodegenerative disorder therapeutics market is anticipated to witness robust growth, with its projected value reaching $28.33 billion in 2029, at a compound annual growth rate (CAGR) of 9.0%. Factors influencing this growth over the forecast period include the surge in demand for targeted therapy and personalized medicine, the increasing number of clinical trials, and escalating healthcare spending. Key trends during this forecast period encompass disease-altering treatments, non-drug interventions, telemedicine, and remote monitoring practices, breakthroughs in technology, precision treatments, digital healthcare solutions, and trials driven by biomarkers._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp_x000D_

_x000D_

#What Are the Core Growth Drivers Propelling the Neurodegenerative Disorder Therapeutics Market Forward?#_x000D_

The rising occurrences of neurodegenerative ailments globally are fueling the growth of the market for neurodegenerative disorder treatments. The rise in elderly population is linked to a higher incidence of these disorders. For instance, data from the World Population Prospects in 2024 suggest that the population aged above 60 years will reach 2.1 billion by 2050, with those aged over 80 years almost tripling to 425 million. As per the Alzheimer’s Association, nearly 5.8 million Americans currently have Alzheimer’s disease, and this figure is expected to increase to approximately 14 million by 2050. The elevated occurrence of neurodegenerative diseases in the aging demographic accentuates the need for therapeutics for neurodegenerative disorders, thus stimulating the market for these treatments._x000D_

_x000D_

#What Segment Types Define the Neurodegenerative Disorder Therapeutics Market Structure?#_x000D_

The neurodegenerative disorder therapeutics market covered in this report is segmented –_x000D_

_x000D_

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types_x000D_

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types_x000D_

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics_x000D_

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies_x000D_

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids_x000D_

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications_x000D_

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Neurodegenerative Disorder Therapeutics Market?#_x000D_

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Neurodegenerative Disorder Therapeutics Market?#_x000D_

Producers of therapeutics for neurodegenerative disorders are entering into strategic partnerships with both governmental and non-governmental organizations to research and develop treatments for a wide array of neurodegenerative diseases. They are also enhancing their collaboration with other market participants to augment their research and development capabilities, with the aim of creating newer, more effective therapies for neurodegenerative disorders. For instance, NRG Therapeutics, a UK-based company that specializes in therapeutic solutions, announced a partnership with Domainex, a UK-based drug discovery service, in July 2022 to develop treatments for neurodegenerative disorders. Their collaboration would focus on creating innovative small-molecule disease-altering medications intended for the treatment of Parkinson’s disease, motor neuron disease (MND), among other debilitating ongoing neurodegenerative conditions._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report_x000D_

_x000D_

#What Is the Definition of the Neurodegenerative Disorder Therapeutics Market?#_x000D_

Neurodegenerative disorder therapeutics refers to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2818_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theLeqembi Market?

The growing prevalence of Alzheimer’s disease is expected to propel the growth of the Leqembi market. Alzheimer’s disease is a degenerative brain disorder that affects memory, cognition, and behavior. Leqembi reduces beta-amyloid plaques in the brain, helping slow cognitive decline in early Alzheimer’s patients. For instance, in September 2024, the European Brain Council reported that approximately 7 million people in Europe live with Alzheimer’s disease, with the number expected to double by 2030. Therefore, the increasing prevalence of Alzheimer’s disease is driving the growth of the Leqembi market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

#What Growth Opportunities Will Drive the Leqembi Market’s CAGR Through 2034?

The leqembi market size has XX (HCAGR) in recent years. It is expected to rise from $XX million in 2024 to $XX million in 2025 at a CAGR of XX%. Growth was driven by a larger elderly population, more funding for neurodegenerative disease research, improved reimbursement, promising clinical trial data, and increased healthcare spending.

The leqembi market size is expected to grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The forecasted growth is attributed to increased R&D spending, rising awareness of Alzheimer’s early diagnosis, the global prevalence of Alzheimer’s disease, demand for neurodegenerative disorder treatments, and a focus on amyloid plaque reduction. Key trends include advancements in neuroscience R&D, digital health technologies, personalized medicine, and disease-modifying therapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20142

Who Are the Major Industry Players Accelerating Growth in theLeqembi Market?

Major companies operating in the leqembi market include Eisai Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Primary Segments of the Leqembi Market Are Driving Growth and Industry Transformations?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20142&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theLeqembi Market?# Market?

North America was the largest region in the leqembi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Leqembi Market 2025, By The Business Research Company:

Alzheimer’s Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Alzheimer’s Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Lewy Body Dementia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: